Clinical trials such as KEYNOTE-158, KEYNOTE-826, and CHECKMATE-358 explored the use of anti-PD1 antibodies like pembrolizumab and nivolumab in cervical cancers that were either advanced, PD-L1 positive, or previously treated with chemotherapy [79-81]. This evidence concerns the gene CD274 and cervical carcinoma.